SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure as investors express skepticism over the company's aggressive debt-fueled AI infrastructure expansion and recent credit rating concerns. Despite the heavy selling, community sentiment remains deeply divided, with some investors viewing the pullback as an oversold buying opportunity, while others are bracing for further volatility.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility and rapid downward pressure, driven by a combination of forced margin liquidations and concerns over South Korean institutional rebalancing. Community sentiment is deeply polarized, with many traders viewing the current steep decline as a high-risk "falling knife" while others aggressively attempt to buy the dip, pointing to the upcoming 20-for-1 stock split and the highly anticipated US IPO of SK Hynix as potential catalysts for a reversal.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is currently trending as investors debate the impact of its recent government policy tailwinds, such as executive orders and potential CHIPS Act funding, against a backdrop of significant price volatility and speculative sell-offs. While many in the community remain bullish on the long-term potential of its neutral-atom quantum technology and growing military-industrial contracts, others are wary of the stock's recent performance following its SPAC debut, leading to heated discussions about whether the current price represents an undervalued entry point or a liquidity trap.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are experiencing significant volatility as investors react to mixed signals regarding the e-commerce advertising rollout and broader software sector rotation. While some market participants express frustration over short-term price swings and analyst skepticism, many retail investors view the recent pullback as a buying opportunity, emphasizing the company's strong growth potential and the performance of its AI-powered advertising technology.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is experiencing significant volatility and downward pressure as market participants process the recent completion of the TopBuild acquisition and the subsequent distribution of shares. Investors remain focused on the company's long-term integration strategy and potential for future value creation, while the community actively debates whether current price levels represent a strategic entry point or if further dilution and macro headwinds will continue to influence near-term performance.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is currently a focal point for investors debating its long-term potential in autonomous drone and defense technology versus concerns over dilution following recent acquisitions. The stock is trending due to high short interest and speculative chatter regarding a potential short squeeze, with the community closely watching how the company executes its growth strategy ahead of upcoming earnings.

Fluence Energy, Inc. engages in energy storage products and services, and artificial intelligence-enabled digital applications for renewables and storage. Its storage includes Smartstack, Gridstack Pro, Grisdtack, and Ultrastack. The company was founded on June 21, 2021, and is headquartered in Arlington, VA.

Fluence Energy Inc - Ordinary Shares - Class A

Fluence Energy is seeing intense community discussion and volatility following a series of strategic partnership developments with Nvidia and Siemens, fueling bullish sentiment over its role in the critical AI data center infrastructure buildout. While long-term investors highlight the company's multi-billion dollar backlog and software potential as a 'no-brainer,' the stock remains caught in a tug-of-war between retail sentiment, heavy short interest, and ongoing institutional insider selling.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio Inc. is currently trending following positive topline results from its SIGNAL-AA clinical trial, which demonstrated meaningful hair regrowth in alopecia areata patients. Investors are actively debating the stock's future potential, balancing the bullish sentiment from analyst price target upgrades against concerns regarding potential dilution from an underwritten public offering.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and commentators closely monitor the impact of ongoing geopolitical tensions in the Middle East on U.S. market volatility. Community discourse remains heavily polarized, with active debates centered on the administration's foreign policy, the implications of a potential maritime blockade, and the broader economic consequences of current geopolitical strategies.

Factorial Energy, Inc. engages in the development and commercialization of solid-state battery technologies. Its platforms include FEST and Solstice, designed to deliver high-performance, scalable battery solutions for applications in drones, robotics, automotive, and other advanced mobility sectors. The company is headquartered in Billerica, MA.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy Inc

Factorial Energy is experiencing high volatility as investors react to a new strategic partnership with Tulip Tech aimed at drone technology, leading to intense debate over the company's long-term commercial viability. The community is sharply divided between those calling it a promising opportunity with strong automotive backing and others labeling it a speculative SPAC-related play prone to rapid price swings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice

Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let's find out.

Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the...

Are Medical Stocks Lagging  Adagene (ADAG) This Year?

Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the...

Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?

The consensus price target hints at a 60% upside potential for Contineum Therapeutics, Inc. (CTNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...

Are Medical Stocks Lagging  C4 Therapeutics (CCCC) This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.

Contineum Therapeutics to Present at the 2026 RBC Capital Markets Global Healthcare Conference

Contineum Therapeutics Announces Two Upcoming Posters at the American Thoracic Society (ATS) 2026 International Conference

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 49.2% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CTNMContineum Therapeutics Inc. - Ordinary Shares - Class A

Fundamentals

Latest CTNM News